1
|
Viguier M, Pérals C, Poirier B, Battistella M, Aubin F, Bachelez H, Prétet JL, Gheit T, Tommasino M, Touzé A, Gougeon ML, Fazilleau N. Human papilloma virus-16-specific CD8+ T-cell expansions characterize different clinical forms of lichen planus and not lichen sclerosus et atrophicus. Exp Dermatol 2023; 32:859-868. [PMID: 36922453 DOI: 10.1111/exd.14788] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2022] [Revised: 02/22/2023] [Accepted: 02/25/2023] [Indexed: 03/18/2023]
Abstract
Lichen planus (LP) is a cutaneomucosal chronic inflammatory disease characterized by a CD8+ cytotoxic T-lymphocytes (CTL) infiltrate. In erosive oral LP, we found HPV16-specific activated CTL in lesions, supporting a pathogenic contribution of HPV16. Here, we investigated whether a similar scenario occurs in other clinical forms of LP and in lichen sclerosus et atrophicus (LSA), another chronic disease also affecting the mucosa and/or the skin. Blood CTL from LP and LSA patients expressed significant higher levels of granzyme B, perforin and CD107a proteins than healthy donors. Expansions of TCRVß3+ CTL, with presence of TCR clonotypes identical to those previously detected in erosive oral LP, were found both in blood and mucosal/skin lesions of LP, and not of LSA patients. These expansions were enriched with HPV16-specific CD8+ T-cells as shown by their recognition of the E711-20 immunodominant epitope. In LSA patients, the peripheral repertoire of CTL was oligoclonal for TCRVß6+ CTL. Finally, although patients with LP and LSA have developed antibodies against HPV16 capsid L1, antibodies against HPV16 E6 were only observed in patients with LP. Overall, our data collectively suggest an involvement of HPV16-specific CTL in different clinical forms of LP, not only in erosive oral LP, while a different scenario operates in LSA.
Collapse
Affiliation(s)
- Manuelle Viguier
- Department of dermatology, Hôpital Robert-Debré, University of Reims Champagne-Ardenne (URCA), EA7509 IRMAIC, Reims, France
| | - Corine Pérals
- Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity), CNRS U5051, INSERM U1291, University Toulouse III, Toulouse, France
| | | | - Maxime Battistella
- Sorbonne Paris Cité, Service d'Anatomo-Pathologie, Hôpital Saint-Louis, Paris, France
| | - François Aubin
- Service de Dermatologie, Centre Hospitalo-Universitaire (CHU) de Besançon, Université de Franche Comté, Besançon, France
| | - Hervé Bachelez
- Laboratory of Genetics of Skin Diseases, Imagine Institute for Human Genetic Diseases, INSERM U1163, Université de Paris, Paris, France
- Department of Dermatology, APHP Hôpital Saint-Louis, Paris, France
| | - Jean-Luc Prétet
- Centre National de Référence Papillomavirus, Laboratoire de Biologie Cellulaire et Moléculaire, CHU de Besançon, Université Bourgogne Franche Comté, Besançon, France
| | | | - Massimo Tommasino
- IARC, Lyon, France
- IRCCS Istituto Tumori Giovanni Paolo II, Bari, Italy
| | | | | | - Nicolas Fazilleau
- Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity), CNRS U5051, INSERM U1291, University Toulouse III, Toulouse, France
| |
Collapse
|
2
|
Nagao Y, Nakagaki H, Tsuji M. Effect of Oral Care in a Patient with Depression and Burning Mouth Syndrome during the COVID-19 Pandemic. Case Rep Dent 2021; 2021:3039269. [PMID: 34712498 PMCID: PMC8548152 DOI: 10.1155/2021/3039269] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2021] [Revised: 07/05/2021] [Accepted: 10/04/2021] [Indexed: 11/18/2022] Open
Abstract
Burning mouth syndrome (BMS) is a burning sensation that occurs in the mouth without any underlying cause. There is no satisfactory treatment for BMS, so far. Herein, we report the case of a 74-year-old female with untreated depression who presented with BMS. Despite taking antidepressants, she developed suicidal thoughts, particularly due to the increasing number of coronavirus disease 2019 (COVID-19) cases and suicides in Japan. The symptoms of BMS and the oral discomfort were eliminated using a multifaceted approach, which included the following: continuous application of the oral care gel "REFRECARE-H®" to the mucous membranes, regular dental visits, collaboration with medical and dental professionals, and administration of zinc preparations. Her suicidal thoughts had disappeared, and her quality of life, assessed using the visual analogue scale, was improved following the treatment. Dentists should strive to provide oral care, while providing treatment in collaboration with specialists, for the early detection of depression and zinc deficiency in patients with BMS.
Collapse
Affiliation(s)
- Yumiko Nagao
- Department of Public Health, Graduate School of Medicine, Juntendo University, Bunkyo-ku, Tokyo 113-8421, Japan
- Tsuji Dental & Oral Surgery Clinic, Shiragane Machi, Omuta, Fukuoka 836-0052, Japan
| | - Hitomi Nakagaki
- Tsuji Dental & Oral Surgery Clinic, Shiragane Machi, Omuta, Fukuoka 836-0052, Japan
| | - Masahide Tsuji
- Tsuji Dental & Oral Surgery Clinic, Shiragane Machi, Omuta, Fukuoka 836-0052, Japan
| |
Collapse
|
3
|
Campello CP, Pellizzer EP, Vasconcelos BCDE, Moraes SLD, Lemos CAA, Muniz MTC. Evaluation of IL-6 levels and +3954 polymorphism of IL-1β in burning mouth syndrome: A systematic review and meta-analysis. J Oral Pathol Med 2020; 49:961-968. [PMID: 32274841 DOI: 10.1111/jop.13018] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2019] [Revised: 02/29/2020] [Accepted: 03/29/2020] [Indexed: 12/30/2022]
Abstract
This study evaluated IL-6 salivary levels as well as the +3954 polymorphism of IL-1β in patients with burning mouth syndrome and healthy individuals, through case-control studies. This systematic review and meta-analysis followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. We conducted this research in PubMed/MEDLINE, Cochrane Library and Web of Science databases. The risk of bias was measured based in the Newcastle-Ottawa Scale. Researches with a group of patients with burning mouth syndrome and a control group in which the presence of the +3954 polymorphism of IL-1β and/ or IL-6 salivary levels through non-stimulated saliva were evaluated to detect if this interleukin concentrations are increased in patients and if the polymorphism is a risk factor for this syndrome. We identified seven studies with total of 440 participants, 229 patients with burning mouth syndrome and 211 healthy controls, ages 24-84 years old. The female gender was predominant. Patients in the majority of studies did not present increased levels of IL-6 and the +3954 polymorphism of IL-1β is not a risk factor for this syndrome. A few studies researched biomarkers in this pathology and more investigations are required not only to identify salivary levels and the polymorphism evaluated, but also other interleukins and polymorphisms in order to clarify the etiopathogenesis of this syndrome as well as for propose new diagnostic methods and treatments.
Collapse
Affiliation(s)
- Camilla Porto Campello
- Postgraduate Program in Biotechnology, Rede Nordeste de Biotecnologia- RENORBIO, UFRPE/UPE, Recife, Brazil
| | - Eduardo Piza Pellizzer
- Department of Dental Materials and Prosthodontics, Dental School, Universidade Estadual Paulista- UNESP, Araçatuba, Brazil
| | | | | | | | | |
Collapse
|